NASDAQ:BCDA BioCardia (BCDA) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free BCDA Stock Alerts $0.41 -0.01 (-2.40%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.39▼$0.4250-Day Range$0.38▼$0.5852-Week Range$0.36▼$2.92Volume285,725 shsAverage Volume393,580 shsMarket Capitalization$10.55 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get BioCardia alerts: Email Address BioCardia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside882.8% Upside$4.00 Price TargetShort InterestBearish6.17% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 11 Articles This WeekInsider TradingBalancedInsiders Both Buying and SellingProj. Earnings GrowthDecreasingFrom ($0.52) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector747th out of 938 stocksBiological Products, Except Diagnostic Industry119th out of 148 stocks 3.3 Analyst's Opinion Consensus RatingBioCardia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, BioCardia has a forecasted upside of 882.8% from its current price of $0.41.Amount of Analyst CoverageBioCardia has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.17% of the float of BioCardia has been sold short.Short Interest Ratio / Days to CoverBioCardia has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioCardia has recently increased by 927.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioCardia does not currently pay a dividend.Dividend GrowthBioCardia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCDA. Previous Next 2.4 News and Social Media Coverage News SentimentBioCardia has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for BioCardia this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BCDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioCardia insiders have sold just slightly more of their company's stock than they have bought. Specifically, they have bought $49,925.00 in company stock and sold $55,815.00 in company stock. It is common for insiders to sell company stock at intervals simply to diversify their holdings.Percentage Held by Insiders23.90% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.57% of the stock of BioCardia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for BioCardia are expected to decrease in the coming year, from ($0.52) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioCardia is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioCardia is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioCardia has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About BioCardia Stock (NASDAQ:BCDA)BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.Read More BCDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCDA Stock News HeadlinesMarch 28, 2024 | benzinga.comPreview: BioCardia's EarningsMarch 28, 2024 | markets.businessinsider.comBioCardia is about to announce its earnings — here's what to expectMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 28, 2024 | finance.yahoo.comQ4 2023 BioCardia Inc Earnings CallMarch 28, 2024 | americanbankingnews.comBioCardia, Inc. (NASDAQ:BCDA) Short Interest Up 927.5% in MarchMarch 27, 2024 | benzinga.comBioCardia: Q4 Earnings InsightsMarch 27, 2024 | globenewswire.comBioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial ResultsMarch 25, 2024 | americanbankingnews.comBioCardia (BCDA) Scheduled to Post Earnings on WednesdayMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.March 20, 2024 | money.usnews.comBioCardia Inc.March 20, 2024 | globenewswire.comBioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024March 13, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 13, 2024 | globenewswire.comBioCardia and StemCardia Announce Biotherapeutic Delivery PartnershipMarch 12, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 12, 2024 | msn.comBioCardia spikes after Medicare coverage for cell therapy trialMarch 12, 2024 | globenewswire.comBioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure StudyMarch 4, 2024 | markets.businessinsider.comBioCardia Reports Positive Interim Results From Phase III CardiAMP Cell Therapy Heart Failure TrialMarch 4, 2024 | globenewswire.comBioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart FailureFebruary 27, 2024 | finance.yahoo.comBCDA Mar 2024 1.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Aug 2024 0.500 callFebruary 17, 2024 | finance.yahoo.comBCDA Mar 2024 0.500 callFebruary 10, 2024 | msn.comBioCardia Inc Secures Funding Through Private PlacementFebruary 10, 2024 | msn.comBioCardia Inc Conducts Unregistered Equity Securities SaleFebruary 9, 2024 | msn.comBioCardia Launches Pivotal CardiAMP HF II TrialFebruary 8, 2024 | finanznachrichten.deBioCardia, Inc.: BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDAFebruary 8, 2024 | finance.yahoo.comBioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDAFebruary 1, 2024 | msn.comBioCardia to Present CardiAMP and CardiALLO at ConferenceSee More Headlines Receive BCDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCardia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BCDA CUSIPN/A CIK925741 Webwww.biocardia.com Phone(650) 226-0120Fax310-861-5299Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+882.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,910,000.00 Net Margins-2,197.72% Pretax Margin-2,197.72% Return on Equity-645.14% Return on Assets-185.19% Debt Debt-to-Equity RatioN/A Current Ratio0.64 Quick Ratio0.64 Sales & Book Value Annual Sales$1.35 million Price / Sales7.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book1.70Miscellaneous Outstanding Shares25,910,000Free Float19,721,000Market Cap$10.55 million OptionableOptionable Beta1.50 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Peter A. Altman Ph.D. (Age 57)CEO, President & Director Comp: $531kMr. David McClung (Age 61)Chief Financial Officer Comp: $382kMr. Edward M. Gillis (Age 62)Senior Vice President of Devices Comp: $271kDr. Sujith ShettyChief Medical Officer and VP of Clinical & RegulatoryKey CompetitorsOrganovoNASDAQ:ONVOGenetic TechnologiesNASDAQ:GENECoeptis TherapeuticsNASDAQ:COEPChromocell TherapeuticsNYSE:CHROEvaxion Biotech A/SNASDAQ:EVAXView All CompetitorsInsiders & InstitutionsPeter AltmanBought 500 shares on 3/28/2024Total: $195.00 ($0.39/share)Virtu Financial LLCBought 41,348 shares on 2/26/2024Ownership: 0.160%Citadel Advisors LLCSold 3,700 shares on 2/15/2024Ownership: 0.000%Peter AltmanBought 108,108 shares on 2/13/2024Total: $49,729.68 ($0.46/share)Phillip Md Et Al FrostSold 129,802 sharesTotal: $55,814.86 ($0.43/share)View All Insider TransactionsView All Institutional Transactions BCDA Stock Analysis - Frequently Asked Questions Should I buy or sell BioCardia stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioCardia in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCDA shares. View BCDA analyst ratings or view top-rated stocks. What is BioCardia's stock price target for 2024? 2 brokerages have issued 12-month target prices for BioCardia's stock. Their BCDA share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 882.8% from the stock's current price. View analysts price targets for BCDA or view top-rated stocks among Wall Street analysts. How have BCDA shares performed in 2024? BioCardia's stock was trading at $0.6642 on January 1st, 2024. Since then, BCDA shares have decreased by 38.7% and is now trading at $0.4070. View the best growth stocks for 2024 here. Are investors shorting BioCardia? BioCardia saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,010,000 shares, an increase of 927.5% from the February 29th total of 98,300 shares. Based on an average daily volume of 378,600 shares, the days-to-cover ratio is currently 2.7 days. Approximately 6.2% of the company's stock are short sold. View BioCardia's Short Interest. When is BioCardia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our BCDA earnings forecast. How were BioCardia's earnings last quarter? BioCardia, Inc. (NASDAQ:BCDA) released its earnings results on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.05. The firm had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.04 million. BioCardia had a negative net margin of 2,197.72% and a negative trailing twelve-month return on equity of 645.14%. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. When did BioCardia's stock split? Shares of BioCardia reverse split on the morning of Friday, November 3rd 2017. The 1-12 reverse split was announced on Thursday, November 2nd 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 2nd 2017. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of BioCardia own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioCardia investors own include Arotech (ARTX), CytoDyn (CYDY), China Gold International Resources (CGG), BioSolar (BSRC), Blink Charging (BLNK), Aurcana Silver (AUNFF), RecycLiCo Battery Materials (AMY) and When did BioCardia IPO? BioCardia (BCDA) raised $51 million in an initial public offering (IPO) on the week of July 20th 2015. The company issued 3,900,000 shares at a price of $12.00-$14.00 per share. Cantor Fitzgerald & Co. acted as the underwriter for the IPO and Roth Capital Partners and Maxim Group were co-managers. Who are BioCardia's major shareholders? BioCardia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.16%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Mcclung, Peter Altman and Phillip Md Et Al Frost. View institutional ownership trends. How do I buy shares of BioCardia? Shares of BCDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCDA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.